XML 58 R48.htm IDEA: XBRL DOCUMENT
v3.24.3

Significant agreements - Bayer Collaboration Agreement (Details) $ in Thousands, £ in Millions |  | 3 Months Ended | 9 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | ---
May 04, 2023 USD ($) item | Sep. 30, 2024 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2024 USD ($) | Sep. 30, 2023 USD ($) | Dec. 31, 2023 USD ($) | May 04, 2023 GBP (£) item | Dec. 31, 2022 USD ($)
Significant agreements. |  |  |  |  |  |  |  |
Revenue from collaborative arrangement |  | $ 2,676 | $ 5,352 | $ 31,567 | $ 21,645 |  |  |
Deferred revenue |  | 109,191 |  | 109,191 |  | $ 135,194 |  | $ 61,873
Bayer Collaboration Agreement |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |
Number of collaboration targets | item | 2 |  |  |  |  |  | 2 |
Upfront cash payment | $ 45,000 |  |  |  |  |  |  |
Milestone payments receivable | £ |  |  |  |  |  |  | £ 583.5 |
Period to terminate agreement upon written notice for uncured material breach | 90 days |  |  |  |  |  |  |
Number of business days to terminate agreement upon non payment by Bayer | 20 days |  |  |  |  |  |  |
Transaction price | $ 47,500 |  |  |  |  |  |  |
Estimated amount payable to CROs | $ 2,500 |  |  |  |  |  |  |
Expected period for satisfaction of performance obligations | 4 years |  |  |  |  |  |  |
Material rights exercise period | 7 years |  |  |  |  |  |  |
Revenue from collaborative arrangement |  | 834 | $ 434 | 2,496 | $ 434 |  |  |
Deferred revenue |  | $ 43,515 |  | $ 43,515 |  | $ 43,618 |  | $ 0
Bayer Collaboration Agreement | Minimum |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |
Number of candidate compounds into further development | item | 1 |  |  |  |  |  | 1 |
Threshold period to terminate agreement upon written notice by Bayer | 60 days |  |  |  |  |  |  |
Bayer Collaboration Agreement | Maximum |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |
Number of collaboration targets | item | 3 |  |  |  |  |  | 3 |
Milestone payments receivable | £ |  |  |  |  |  |  | £ 194.5 |
Threshold period to terminate agreement upon written notice by Bayer | 90 days |  |  |  |  |  |  |
Bayer Collaboration Agreement | Development and regulatory milestones | Maximum |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |
Milestone payments receivable | £ |  |  |  |  |  |  | 178.3 |
Bayer Collaboration Agreement | Across all three potential target programs |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |
Milestone payments receivable | £ |  |  |  |  |  |  | £ 534.9 |

X
- Definition Number of collaboration targets under the collaboration agreement. + References No definition available. + Details
Name: | bcyc_CollaborationAgreementNumberOfTargets
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of tiered sales milestone payments. + References No definition available. + Details
Name: | bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of candidate compounds into further development under the collaboration and license agreement. + References No definition available. + Details
Name: | bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of upfront cash payment received from collaborative arrangement. + References No definition available. + Details
Name: | bcyc_CollaborativeArrangementUpfrontCashPaymentReceived
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Estimated amount of reimbursement payable for services provided by Contract Research Organizations (CROs). + References No definition available. + Details
Name: | bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The duration of material rights exercised or expired. + References No definition available. + Details
Name: | bcyc_MaterialRightsExerciseOrExpiryTerm
Namespace Prefix: | bcyc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents period over which performance obligations will be performed. + References No definition available. + Details
Name: | bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed
Namespace Prefix: | bcyc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of allocated determined transaction price under revenue recognition arrangement. + References No definition available. + Details
Name: | bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of business days to terminate agreement upon non payment by Bayer. + References No definition available. + Details
Name: | bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer
Namespace Prefix: | bcyc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period to terminate agreement upon written notice by Bayer. + References No definition available. + Details
Name: | bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer
Namespace Prefix: | bcyc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period to terminate agreement upon written notice for uncured material breach. + References No definition available. + Details
Name: | bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach
Namespace Prefix: | bcyc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcyc_BayerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bcyc_AchievementOfMilestoneAxis=bcyc_DevelopmentAndRegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bcyc_AchievementOfMilestoneAxis=bcyc_MilestoneAcrossAllPotentialTargetProgramsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |